CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) Sees Significant Increase in Short Interest

CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) saw a significant increase in short interest in November. As of November 15th, there was short interest totalling 7,860,000 shares, an increase of 391.3% from the October 31st total of 1,600,000 shares. Based on an average daily volume of 63,190,000 shares, the short-interest ratio is presently 0.1 days. Currently, 30.0% of the company’s stock are short sold.

Insider Transactions at CERo Therapeutics

In other news, major shareholder Bioventures Opportunities G. Yk sold 3,250,000 shares of the business’s stock in a transaction that occurred on Thursday, October 10th. The shares were sold at an average price of $0.10, for a total value of $325,000.00. Following the completion of the transaction, the insider now directly owns 22,620,783 shares in the company, valued at approximately $2,262,078.30. The trade was a 12.56 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Stuart M. Sloan sold 532,486 shares of CERo Therapeutics stock in a transaction that occurred on Wednesday, September 25th. The shares were sold at an average price of $0.10, for a total transaction of $53,248.60. Following the completion of the transaction, the insider now directly owns 21,067,956 shares in the company, valued at $2,106,795.60. This trade represents a 2.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 18.00% of the stock is owned by insiders.

CERo Therapeutics Stock Performance

Shares of CERo Therapeutics stock traded up $0.06 during trading on Wednesday, hitting $0.20. The company’s stock had a trading volume of 63,552,133 shares, compared to its average volume of 20,757,527. CERo Therapeutics has a 52 week low of $0.06 and a 52 week high of $12.80. The stock has a 50-day moving average price of $0.12 and a two-hundred day moving average price of $0.29.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc, an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.